Page 24 - Commercialization Of The National Backbone Infrastructure News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Commercialization of the national backbone infrastructure. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Commercialization Of The National Backbone Infrastructure Today - Breaking & Trending Today

PCG Digital: Soligenix's Upcoming Catalysts Highlight Growth Potential as it Sheds Light on its Commercialization of SGX301


(3)
New York, New York (Newsfile Corp. - February 9, 2021) - PCG Digital: Soligenix (NASDAQ: SNGX) continues to build excitement for its SGX301 candidate following strong Phase 3 data and commercialization plans. The company recently held an investor webcast to further explain the company s plans for commercializing its ground-breaking SGX301 candidate for the treatment of cutaneous T-cell lymphoma (CTCL).
Here are some key takeaways from the commercialization Q&A:
1. Soligenix will commercialize SGX301 in the U.S. on its own
During the presentation, the company noted that after conducting necessary due diligence and simulating different routes to commercialization, it was determined that a partnership would not be the best solution for shareholders. The licensing landscape and CTCL s small, orphan market were the key drivers behind the decision. Considering that the average biopharmaceutical licensing deal, a Phase 3 licensor will typically retain no more than 40 ....

New York , United States , Chris Schaber , Jonathan Guarino , Zack Research Updates Soligenix , York Newsfile Corp , Cap Research , Advisory Inc , Digital Holdings , Multiple Near Term Catalysts Anticipated , New Drug Application , Clinical Study Report , Prescription Drug User Fee Act , American Academy , Dermatology Meeting , Investigative Dermatology Meeting , Research Updates Soligenix , Positive Report , Small Cap Research , Paid Advertising , Securities Act , புதியது யார்க் , ஒன்றுபட்டது மாநிலங்களில் , கிறிஸ் ஸ்கேபர் , ஜொனாதன் குவாரினோ , தொப்பி ஆராய்ச்சி ,

POINT Biopharma Signs Exclusive License Agreement with CanProbe for the Commercialization of a Neuroendocrine Tumor Treatment


(1)
TORONTO, Jan. 12, 2021 (GLOBE NEWSWIRE) POINT Biopharma Inc. (POINT), a radiopharmaceutical company dedicated to bringing the many benefits of precision radioligand therapy to cancer patients, today announced that it has signed a licensing and commercialization agreement with CanProbe for exclusive rights to Lutetium - 177 Octreotate (Lu-DOTATATE) for the treatment of neuroendocrine cancer. CanProbe, a joint venture between the University Health Network (UHN) and the Centre for Probe Development and Commercialization (CPDC), developed Lu-DOTATATE as it is being used in 167 neuroendocrine tumor (NET) patients in a 180-patient trial with enrollment completed.
CanProbe s NET clinical program has helped many patients in Ontario who previously had no other options for treatment, says Dr. Joe McCann, Chief Executive Officer of POINT Biopharma. We are excited to extend access to this treatment by leveraging CanProbe s intellectual property to seek regulatory approvals, ....

United States , Octreotate Lu , Joe Mccann , Kostenloser Wertpapierhandel , Luke Brzozowski , Biopharma Inc , University Health Network , Canadian Centre Of Excellence , Health Canada , Centre For Probe Development , Corporate Affairs , Probe Development , Chief Executive Officer , Canadian Centre , Bio Pharma , ஒன்றுபட்டது மாநிலங்களில் , ஓஹோ ம்க்க்யாந் , லூக் பிறரோஸ்வ்வ்ஸ்கி , பல்கலைக்கழகம் ஆரோக்கியம் வலைப்பின்னல் , கனடியன் மையம் ஆஃப் சிறப்பானது , ஆரோக்கியம் கனடா , மையம் க்கு ப்ரோப் வளர்ச்சி , பெருநிறுவன வாழ்க்கைத்தொழில்கள் , ப்ரோப் வளர்ச்சி , தலைமை நிர்வாகி அதிகாரி , கனடியன் மையம் ,